IGD4033 Ligandrol CAS:1165910-22-4

Details:

Ligandrol LGD 4033 powder is a selective androgen receptor modulator a novel non-steroidal, oral SARM that binds to AR with high affinity and selectivity, class of androgen receptor (AR) ligands that is tissue selective, developed to treat muscle wasting associated with cancer, acute and chronic illness and age-related muscle loss. LGD-4033 is expected to produce the therapeutic benefits of testo sterone with improved safety, tolerability and patient acceptance due to tissue-selective mechanism of action and an oral route of administration.

Function

LGD-4033 works by tying androgen receptors selectively. It shows anabolic activity in the bones and muscles instead of harmfully affecting the prostate and sebaceous glands which usually happens when using steroids. LGD-4033 just concluded a study called Phase I Multiple Ascending Dose which included fit volunteers. This was an unplanned, double bind analysis stage that included a placebo.

Ligandrol LGD 4033 powder is a selective androgen receptor modulator a novel non-steroidal, oral SARM that binds to AR with high affinity and selectivity, class of androgen receptor (AR) ligands that is tissue selective, developed to treat muscle wasting associated with cancer, acute and chronic illness and age-related muscle loss. LGD-4033 is expected to produce the therapeutic benefits of testo sterone with improved safety, tolerability and patient acceptance due to tissue-selective mechanism of action and an oral route of administration.

Function

LGD-4033 works by tying androgen receptors selectively. It shows anabolic activity in the bones and muscles instead of harmfully affecting the prostate and sebaceous glands which usually happens when using steroids. LGD-4033 just concluded a study called Phase I Multiple Ascending Dose which included fit volunteers. This was an unplanned, double bind analysis stage that included a placebo.